Announcement of Taiwan FDA: Approval for Bionime’s iFree Continuous Glucose Monitoring System

Bionime’s iFree Continuous Glucose Monitoring System received approval from the TFDA(Taiwan Food and Drug Administration) on October 13th. It has obtained the license categorized in Second-Class Medical Device.

The iFree Continuous Glucose Monitoring System (iFree CGM) is indicated for detecting glycemic trends and managing glucose levels. It can help detect hyperglycemia and hypoglycemia, facilitate timely intervention and further enhance life quality. iFree CGM can benefit not only the diabetes patients but also people who need it for glucose management. 

2023 is the 20th anniversary of Bionime. Receiving TFDA’s approval for iFree CGM is a great milestone for Bionime. We will continue to enhance the diabetes care solutions and will provide an affordable and competitive CGM for all users globally!